Skye Bioscience Reports that Emerald Health Therapeutics Shareholders Voted in Favor of Plan of Arrangement

San Diego, California, Aug. 19, 2022 (GLOBE NEWSWIRE) —

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reports that the shareholders of Emerald Health Therapeutics, Inc. (“Emerald” or the “Company”) (CSE: EMH; OTCQB: EMHTF) today approved the proposed plan of arrangement. This development marks a significant milestone in Skye Bioscience’s efforts to advance its innovative treatment for glaucoma.

Impact on Individuals:

As an individual, this news may not have an immediate impact on you. However, if you or a loved one is suffering from glaucoma, this approval of the plan of arrangement could eventually lead to the development of a new and effective treatment option. It is important to stay informed about advancements in medical research and pharmaceutical developments.

Impact on the World:

The approval of the proposed plan of arrangement by the shareholders of Emerald Health Therapeutics has the potential to make a significant impact on the world of healthcare. If Skye Bioscience’s synthetic cannabinoid derivative proves to be successful in treating glaucoma, it could revolutionize the way this common eye condition is managed, potentially improving the quality of life for millions of people worldwide.

Conclusion:

In conclusion, the approval of the plan of arrangement by Emerald Health Therapeutics shareholders is a positive step forward for Skye Bioscience and the field of pharmaceutical research. This development highlights the importance of continued innovation and collaboration in the pursuit of novel treatments for medical conditions. Stay tuned for further updates on the progress of this exciting new venture.